Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

A genomic study of chronic blood cancer - a precursor to leukaemia - has discovered gene mutations that could enable diagnosis using only a blood test, avoiding the need for an invasive and painful bone marrow biopsy.

27 Sep 2011

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Research in Switzerland could help reduce the time taken to develop vaccines against cancer tumours.

27 Sep 2011

Scientists identify a way that chemotherapy causes platelet numbers to drop

Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.

26 Sep 2011

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.

26 Sep 2011

Study identifies areas for cancer care cost and quality improvements

With cancer care costs rising at an unprecedented rate, The US Oncology Network, one of the nation's largest networks of community-based oncologists dedicated to advancing cancer care in America, reported a study that identified areas where both the cost and quality of care could be improved.

26 Sep 2011

Janssen Biotech receives FDA approval for Remicade to treat UC in children

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

26 Sep 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

23 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

22 Sep 2011

GE Healthcare unveils ultra-low dose CT technology with profound image clarity

Emphasizing its commitment to low-dose medical imaging, GE Healthcare today announced 510(k) clearance of its revolutionary Computed Tomography (CT) technology, called Veo,* which may help physicians deliver accurate diagnoses by enabling profound CT image clarity at dramatically lower dose. Veo represents the CT industry’s first Model-based Iterative Reconstruction (MBIR) technique, and is already available on GE Discovery CT750 HD systems in Europe, Canada and regions of Asia.

20 Sep 2011

New insight into how nervous system regulates immunity

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science.

17 Sep 2011

Leica Microsystems bringing digital pathology excellence to the hematopathology workshop

Leica Microsystems, world-leading providers of Total Digital Pathology solutions, are a proud platinum sponsor of this year’s joint workshop of the Society for Hematopathology and the European Association for Haematopathology (SH/EAHP) being held at the Ritz-Carlton Marina Del Rey, Los Angeles, USA, from October 27-29, 2011.

15 Sep 2011

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

While therapeutic advances have improved survival of patients with follicular lymphoma (FL), it remains an incurable disease with inevitable relapse. This underscores the need for therapies and strategies to extend the duration of remission without significantly increasing toxicity and while maintaining quality of life.

15 Sep 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Pulitzer photojournalist with lymphoma films his experiences

Diagnosed at age 48 with a potentially deadly form of lymphoma, Pulitzer Prize-winning photojournalist John Kaplan turned the lens on himself and chronicled his experience in a moving visual journal. Kaplan's new film, Not As I Pictured, is now showing on PBS stations nationwide.

8 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years and 75 percent in patients who were in remission at the time of the transplant.

2 Sep 2011

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

Lymphoma News and Research

Further Reading

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Scientists identify a way that chemotherapy causes platelet numbers to drop

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Study identifies areas for cancer care cost and quality improvements

Janssen Biotech receives FDA approval for Remicade to treat UC in children

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

GE Healthcare unveils ultra-low dose CT technology with profound image clarity

New insight into how nervous system regulates immunity

Leica Microsystems bringing digital pathology excellence to the hematopathology workshop

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pulitzer photojournalist with lymphoma films his experiences

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News